<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243489</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571ADE75T</org_study_id>
    <secondary_id>2010-018339-16</secondary_id>
    <nct_id>NCT01243489</nct_id>
  </id_info>
  <brief_title>Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation</brief_title>
  <acronym>Crescendo</acronym>
  <official_title>CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crolll Gmbh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study on patient's compliance in clinical workaday life aims to assess and to improve
      CML treatment in Germany by means of adherence supporting measures and to increase adherence
      awareness by physicians and patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients compliance</measure>
    <time_frame>12 months</time_frame>
    <description>To assess patients compliance before and after intervention by comparison of the number of imatinib (Glivec®) tablets taken before and after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>12 months</time_frame>
    <description>to correlate the compliance assessed by pill count (conventional pill count and pill count using SmartBlister in selected centers) with the results obtained by the questionnaires and interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy of imatinib</measure>
    <time_frame>12 months</time_frame>
    <description>to monitor the efficacy of imatinib as assessed by cytogenetics and PCR testing (BCR-ABL load, % IS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Myelogenous Leukemia (CML)</condition>
  <arm_group>
    <arm_group_label>patient diary</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>compliance supporting measure: patients uses patient diary from month 6 to 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Information service &quot;Leben mit CML&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>compliance supporting measure: patient uses the Information service &quot;Leben mit CML&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>compliance supporting measures</intervention_name>
    <description>Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service &quot;Leben mit CML&quot; or the use of a daily diary</description>
    <arm_group_label>patient diary</arm_group_label>
    <arm_group_label>Information service &quot;Leben mit CML&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt; 18 years) CML patients in the chronic phase

          -  Medical history of cytogenetically confirmed CML-CP by the presence of the
             Philadelphia chromosome on bone marrow aspirates (a minimum of 20metaphases is
             required; FISH cannot be used); Philadelphia chromosome negative but BCR- ABL-positive
             CML patients can be included

          -  ECOG performance status of &lt; 2

          -  Imatinib treatment for at least 1 year and showing CCyR or MMR

          -  Prior treatment with chemotherapeutics such as hydroxyurea or interferon- alpha is
             allowed

          -  Prior periods of accelerated phases are allowed

          -  Negative pregnancy test for female patients of childbearing potential within 7 days
             before initiation of study drug

          -  Ability to understand and willingness to sign a written informed consent document
             prior to any study related screening procedures

          -  Written informed consent, including the consent to be called for interviews by the
             external, neutral institution.

        Exclusion Criteria:

          -  Patients with prior blast crisis or stem cell transplantation

          -  Patients with severe medical condition(s) that in the discretion of the investigator
             prohibits participation in the study (e.g., clinically significant heart diseases,
             uncontrolled diabetes, active or uncontrolled infection, impaired gastrointestinal
             function/diseases)

          -  Treatment with drugs or substances, especially those known to modify the cytochrome
             P450 activity, should be either discontinued or exchanged by different medication (see
             link for complete list of these medications:
             http://medicine.iupui.edu/flockhart/table.htm.)

          -  Pregnant or breastfeeding women

          -  Male or female of childbearing potential unwilling to use contraceptive precautions
             throughout the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Hochhaus, Professor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Jena, Klinik für Innere Medizin II</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Celle</name>
      <address>
        <city>Celle</city>
        <zip>29221</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Dresden, Gemeinschaftspraxis Dres. Göhler &amp; Dörfel</name>
      <address>
        <city>Dresden</city>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämatologie - Onkologie, BAG Freiberg-Richter / Jacobasch / Illmer / Wolf</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Erfurt</city>
        <zip>99085</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Antonius-Hospital, Klinik für Hämatologie und Onkologie</name>
      <address>
        <city>Eschweiler</city>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IFS - Interdisziplinäres Facharztzentrum Sachsenhausen</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologische Schwerpunktpraxis, Dres. Michael Metz, Andreas Ammon, Dirk Meyer</name>
      <address>
        <city>Göttingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediProjekt, Gesellschaft für Medizinstatistik und Projektentwicklung</name>
      <address>
        <city>Hannover</city>
        <zip>30171</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Innere Medizin, Onkologie und Hämatologie, Dr. Hahnfeld</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Innere Medizin II</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Siehl, Dr. Söling und Prof. Dr. Hirschmann</name>
      <address>
        <city>Kassel</city>
        <zip>34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis, Dres. Neise, Lollert</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis, Dres. Ursula Vehling-Kaiser, Doris Greif</name>
      <address>
        <city>Landshut</city>
        <zip>84028</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Schwerpunktpraxis Dr. Tschechne</name>
      <address>
        <city>Lehrte</city>
        <zip>31275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis, Dres. Uthgenannt, Kisro, Weber</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkonet GbR, Praxis Dres. Weidenbach &amp; Balser</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologisch onkologische Schwerpunktpraxis</name>
      <address>
        <city>Mayen</city>
        <zip>56727</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordbadpraxis</name>
      <address>
        <city>München</city>
        <zip>80797</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämato - Onkologische Praxisgemeinschaft, Dr. Schmidt</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Walter</name>
      <address>
        <city>Paderborn</city>
        <zip>33102</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachärzte für Innere Medizin, Hämatologie &amp; Onkologie Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>56727</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-Onkologische Gemeinschaftspraxis Würselen</name>
      <address>
        <city>Würselen</city>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Innere Medizin, Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Würzburg</city>
        <zip>97970</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2010</study_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>compliance</keyword>
  <keyword>compliance supporting measures</keyword>
  <keyword>complete cytogenetic response</keyword>
  <keyword>mayor molecular remission</keyword>
  <keyword>Philadelphia chromosome</keyword>
  <keyword>BCR-ABL</keyword>
  <keyword>Imatinib</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <keyword>smart blister</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

